Nexell Therapeutics Inc.
The Irvine developer of cell therapies for cancer and other diseases reported a loss of $8.3 million, or 53 cents a share, for the second quarter, compared with a loss of nearly $9 million, or 57 cents a share, for the same period last year. Revenue climbed to $4.6 million from $1.6 million.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
